MedPath

Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum

Not Applicable
Completed
Conditions
Renal Function Disorder
Hepatic Dysfunction Transient
Registration Number
NCT02013596
Lead Sponsor
Zhihong LU
Brief Summary

The purpose of this study is to compare the effect of TEAS pretreatment and treatment on hepatic and renal dysfunction induced by pneumoperitoneum in patients undergoing laparoscopic surgeries.

Detailed Description

Patients were randomly assigned to three groups, control group and two intervention groups, receiving TEAS before and after general anesthesia induction respectively. TEAS was given through electrodes attached to acupoints. The time for TEAS was 30min. Venous blood samples were collected before and 20min after pneumoperitoneum. Hepatic and renal function index including AST, ALT, ALP, BUN, Cr were measured.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
168
Inclusion Criteria
  • Age>18yrs,<60yrs;
  • ASA 1-2;
  • Scheduled for laparoscopic surgery under general anesthesia;
  • Informed consented
Exclusion Criteria
  • Patients with hepatic or renal dysfunction;
  • Patients with severe hypertension or cardiac dysfunction;
  • Patients with severe pulmonary disease;
  • Patients with hemoglobin<100g/L

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Incidence of renal or hepatic dysfunction20min after pneumoperitoneum

percentage of patients with renal or hepatic dysfunction

Secondary Outcome Measures
NameTimeMethod
Change of hepatic function20min after pneumoperitoneum

the increase of hepatic ALT and AST after pneumoperitoneum

Change of renal function20min after pneumoperitoneum

Change of BUN and Cr after pneumoperitoneum

Trial Locations

Locations (1)

Xijing Hospital, Fourth Military Medical University

🇨🇳

Xi'an, Shaanxi, China

Xijing Hospital, Fourth Military Medical University
🇨🇳Xi'an, Shaanxi, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.